JAMP Pharma

Your pharmacy’s generic partner.

We are committed to continuously improving the supply and access to affordable medicines for all Canadians.

Proudly Canadian, we provide continuous access to high quality and affordable generic products: this is our promise.

JAMP Pharma Group Acquires a Pharmaceutical Manufacturing Facility in Lévis, Quebec

This transaction strengthens JAMP Pharma Group’s position as an industry leader and addresses the increasing demand for locally manufactured pharmaceutical products. Boucherville, Quebec, February 29, 2024 — JAMP Pharma Group, a leading company in the Canadian pharmaceutical industry for over 35 years, announces today, subject to Superior Court approval and…
February 29, 2024
News and events
JAMP Pharma Group announces the commercial launch and product availability for Pr Jamteki TM, the first biosimilar of Stelara® (ustekinumab) in Canada

PrJamtekiTM was the first ustekinumab biosimilar to receive marketing authorization in Canada1. PrJamteki TM is the second biosimilar developed under the exclusive partnership in Canada between JAMP Pharma Group and Alvotech. This second biosimilar launch in 2 years is a very important step, enabling BioJAMPTM to reinforce its leadership role…
March 1, 2024
BIOJAMP, Press release
Alvotech and JAMP Pharma announce receipt of marketing authorization for PrJamtekiTM (AVT04), the first biosimilar of Stelara® (ustekinumab)

PrJamtekiTM is the second biosimilar developed under this partnership that receives marketing authorization in Canada. REYKJAVIK, ICELAND & BOUCHERVILLE, QC (November 9, 2023) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and JAMP Pharma Group (“JAMP…
November 14, 2023
BIOJAMP, New launches, News and events, Press release

JAMP Pharma

Proudly Canadian, we provide continuous access to high quality and affordable generic products: this is our promise.

JAMP Pharma Group Acquires a Pharmaceutical Manufacturing Facility in Lévis, Quebec

JAMP Pharma Group announces the commercial launch and product availability for Pr Jamteki TM, the first biosimilar of Stelara® (ustekinumab) in Canada

Alvotech and JAMP Pharma announce receipt of marketing authorization for PrJamtekiTM (AVT04), the first biosimilar of Stelara® (ustekinumab)